UNSPSC 51132200: Combination non-opioid analgesics

This classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics which do not bind to opioid receptors, which do not derive from opium or morphine, which are non-addictive, and which are not narcotics, and which therefore bear the term NON-OPIOID ANALGESICS. Typical non-opioid analgesic constituents are acetaminophen (paracetamol), aluminum hydroxide, aspirin, caffeine, etc.

UNSPSC 51132200 Combination non-opioid analgesics is a Class code encompassing pharmaceutical products and related medical supplies that state and local governments procure for community health, emergency response, and public health initiatives. Recent state and local solicitations under this code show procurement of naloxone and opioid antagonists, generic pharmaceuticals, and over-the-counter products distributed through established supply chains and authorized wholesalers. Issuing bodies span state health and human services agencies, county health departments, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Procurement typically flows through competitive bidding processes (IFB, RFP) with requirements for FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, and supply through authorized pharmaceutical wholesalers. Vendors must maintain substantial insurance coverages, comply with E-Verify and drug-free workplace requirements, and accept fixed-fee or net-pricing models with administrative fees.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB (60459723LAS) on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response deadline July 26, 2023. The Texas Health and Human Services Commission issued a Request for Information (HHS0017013) in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring direct contracting models outside traditional pharmacy benefit manager relationships. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and awarded products effective July 1, 2026; this cooperative vehicle extends to participating states including Oregon. Manufacturers supplying MMCAP must work through three authorized wholesalers and comply with pricing structures ranging from flat-fee to WAC-minus models, with evaluation weighted 75 percent on price competitiveness and 25 percent on compliance, EDI capability, and administrative fee acceptance.